Tumor microenvironment and the response to anticancer therapy
- PMID: 12496469
- DOI: 10.4161/cbt.1.5.157
Tumor microenvironment and the response to anticancer therapy
Abstract
Human solid tumors are invariably less well oxygenated than normal tissues. This leads to resistance to radiotherapy and anticancer chemotherapy, as well as predisposing for increased tumor metastases. Prolonged hypoxia of the tumor tissue also leads to necrosis, and necrotic regions are also characteristic of solid tumors. These two characteristics-hypoxia and necrosis-represent clear differences between tumors and normal tissues and are potentially exploitable in cancer treatment. This review focuses on the phenomenon of tumor hypoxia and how hypoxia and its accompanying necrosis can be exploited in therapy. One such strategy is to use drugs that are toxic only under hypoxic conditions, and the first drug of this class to enter clinical testing, tirapazamine, is showing considerable promise. The second way to exploit hypoxia is to take advantage of the selective induction under hypoxia of the transcription factor HIF-1 (hypoxia-inducible factor 1). Gene therapy strategies based on this are in development. Finally, tumor hypoxia can be exploited using live obligate anaerobes that have been genetically engineered to express enzymes that can activate non-toxic prodrugs into toxic chemotherapeutic agents.
Similar articles
-
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.Mol Med Today. 2000 Apr;6(4):157-62. doi: 10.1016/s1357-4310(00)01677-4. Mol Med Today. 2000. PMID: 10740254 Review.
-
Tumor hypoxia in cancer therapy.Methods Enzymol. 2007;435:297-321. doi: 10.1016/S0076-6879(07)35015-5. Methods Enzymol. 2007. PMID: 17998060
-
Hypoxia: targeting the tumour.Anticancer Agents Med Chem. 2006 Jul;6(4):281-6. doi: 10.2174/187152006777698169. Anticancer Agents Med Chem. 2006. PMID: 16842231 Review.
-
Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?Strahlenther Onkol. 2003 Dec;179(12):801-11. doi: 10.1007/s00066-003-1150-9. Strahlenther Onkol. 2003. PMID: 14652668 Review.
-
Hypoxic sensitizer and cytotoxin for head and neck cancer.Ann Acad Med Singap. 1996 May;25(3):397-404. Ann Acad Med Singap. 1996. PMID: 8876907 Review.
Cited by
-
Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.Virchows Arch. 2013 May;462(5):547-56. doi: 10.1007/s00428-013-1404-6. Epub 2013 Apr 3. Virchows Arch. 2013. PMID: 23549732
-
Long-term severe hypoxia adaptation induces non-canonical EMT and a novel Wilms Tumor 1 (WT1) isoform.Cancer Gene Ther. 2024 Aug;31(8):1237-1250. doi: 10.1038/s41417-024-00795-3. Epub 2024 Jul 8. Cancer Gene Ther. 2024. PMID: 38977895 Free PMC article.
-
NMR metabolomic profiling reveals new roles of SUMOylation in DNA damage response.J Proteome Res. 2010 Oct 1;9(10):5382-8. doi: 10.1021/pr100614a. J Proteome Res. 2010. PMID: 20695451 Free PMC article.
-
Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.J Cancer Res Clin Oncol. 2010 Mar;136(3):447-56. doi: 10.1007/s00432-009-0675-4. Epub 2009 Sep 16. J Cancer Res Clin Oncol. 2010. PMID: 19760195
-
A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship.Molecules. 2022 May 9;27(9):3036. doi: 10.3390/molecules27093036. Molecules. 2022. PMID: 35566385 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
